NeuMoDx Molecular Raises $21M in Series B Financing

NeuMoDx Molecular, Inc., an Ann Arbor, MI-based diagnostics company developing a new platform for high throughput, low cost molecular testing, raised $21m in Series B financing.

The round was led by Pfizer Ventures with participation from Baird Capital, Venture Investors and existing investors Arboretum Ventures and The Wolverine Venture Fund.

Led by Jeff Williams, Founder and CEO, NeuMoDx Molecular develops the NeuMoDx 500 Molecular IVD System, a fully automated, random access platform capable of performing RNA and DNA-based assays.

The company intends to use the funds to develop its NeuMoDx 500 Molecular IVD System, pursue clinical trials and regulatory approvals for its first assays.



Join the discussion